Macquarie retained its Outperform rating on Cohance Lifesciences despite a weaker-than-expected June quarter, while Jefferies maintained Underperform as sales declines across businesses pushed EBITDA close to break-even.
Macquarie retained its Outperform rating on Cohance Lifesciences despite a weaker-than-expected June quarter, while Jefferies maintained Underperform as sales declines across businesses pushed EBITDA close to break-even.
<iframe src="https://hindustansphere.com/embed/cluster/3c81030d6d4c6b80b991b4352c125175e5271442" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Cohance Lifesciences Q1 Review: Brokerages Split After Earnings Slump — Check Potential Upside, Target Price"></iframe>
